A detailed history of Bivin & Associates, Inc. transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Bivin & Associates, Inc. holds 800 shares of ORMP stock, worth $2,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
800
Previous 800 -0.0%
Holding current value
$2,000
Previous $7,000 42.86%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 06, 2022

BUY
$8.19 - $13.89 $819 - $1,389
100 Added 14.29%
800 $7,000
Q4 2021

Feb 14, 2022

BUY
$12.98 - $29.75 $9,086 - $20,825
700 New
700 $10,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $97.1M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Bivin & Associates, Inc. Portfolio

Follow Bivin & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bivin & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bivin & Associates, Inc. with notifications on news.